Adult onset Still’s disease in the elderly: a case-based literature review

Arash Mollaeian1*, Jingjing Chen1, Nina N. Chan1, Gregory A. Nizialek1,2 and Christopher J. Haas1,2

Abstract

Background: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder that classically presents with high spiking fevers, evanescent rash, and arthritis. The diagnosis is one of exclusion and can be further complicated by atypical presentations, particularly in elderly patients in whom AOSD is very rare.

Case presentation: A case of AOSD in a 73-year-old woman with a non-classic presentation, leading to delayed diagnosis and management, is presented along with a review of the English literature for AOSD cases in elderly people over 70 years of age. Thirty nine case reports and series were identified and the current case was added, totaling 42 individual cases. Significant findings included a four-times higher prevalence in females, a higher prevalence of macrophage activation syndrome despite lower mortality, the presence of pruritic rash in almost one fifth of the cases, and high prevalence of delayed diagnosis.

Conclusions: AOSD in the elderly may vary from the classic criteria described in the medical literature and may lead to delayed diagnosis and management. Further evaluation and better characterization of AOSD in the elderly remains an area of interest.

Keywords: Adult onset Still’s disease, Autoinflammatory disorders, Hyperferritinemia, Arthritis, Elderly, Case report

Background

Adult onset Still’s disease (AOSD) is one cause of fever of unknown origin in adults and a diagnostic challenge for clinicians. Due to its rarity, the epidemiology of AOSD is not well understood, however a prevalence of 1 to 34 cases per million people has been reported [1]. While a slight female predominance exists, the overall incidence in the female and male general population seems to be equal [1, 2]. The overwhelming majority of cases present between the ages of 16–35, however 10% of cases present after 50 years of age [1–3].

AOSD in the elderly is rare and not well studied, therefore its prevalence and characteristics in this age group are not well understood. This can potentially lead to misdiagnosis or delayed diagnosis in this population, subsequently leading to delay in proper management and possible increase in complications. We present a case of AOSD in a 73-year-old woman with an atypical presentation that led to a 6-month delay in diagnosis and management. As the age of the patient was one major factor for diagnostic delay, we reviewed and analyzed the published English literature, after performing a Medline and EMBASE search for case reports and case series pertaining to AOSD in patients older than 70, and summarize the results.

Case presentation

A 73-year-old woman with past medical history of diabetes mellitus, degenerative disc disease, and osteoarthritis presented to the emergency department due to progressively worsening back pain for 1 month. The patient described the pain as intermittent, yet progressive, becoming constant, worsening with movement and lifting, and radiating to bilateral thighs without associated numbness, weakness, morning stiffness, or...
constitutional symptoms. She endorsed a prior history of urinary incontinence, unchanged during the current presentation. Physical exam was significant for low grade fever at 38.1°C, L5-S1 spinal tenderness, and a positive bilateral straight leg raise. She had an unlimited active and passive range of motion of the bilateral lower extremities but was noted to have significant pain on knee extension and flexion, without joint swelling or erythema. Initial laboratory findings were significant for leukocytosis (20.6 k/uL), moderate microcytic hypochromic anemia, and mild transaminase elevation. Computed tomography (CT) of the lumbar spine revealed diffuse degenerative changes and spinal stenosis at L4-L5, without mass, fluid collection, fracture or dislocation (Fig. 1). Magnetic resonance imaging (MRI) of the cervical and lumbar spine was negative for cord compression or epidural abscess, however was worrisome for possible discitis/osteomyelitis at C6-C7 and L2-L5 levels (Fig. 2). The patient was started on empiric broad-spectrum antibiotics and admitted to the medical floor.

Further workup revealed markedly elevated inflammatory markers, specifically a ferritin of 9617 ng/mL (Table 1). The patient continued to spike quotidian fevers up to 39°C (Fig. 3) despite broad-spectrum antibiotics, persistently negative blood cultures, and a negative tuberculosis T-spot. CT scans of chest, abdomen and pelvis revealed a moderate left-sided pleural effusion, multiple mediastinal lymph nodes with the largest measuring 1.8 × 1.0 cm, and mild ascites (Fig. 4). CT-guided biopsy of the superior aspect of the L5 vertebrae revealed normal bone marrow and was negative for bacterial, fungal, and acid-fast bacillus organisms, ruling out infectious and non-infectious osteomyelitis. Additional diagnostic evaluation including human immunodeficiency virus (HIV), Syphilis, Brucella, Cryptococcus, Hepatitis C, and Histoplasma were all negative. Transesophageal echocardiogram to exclude culture-negative infective endocarditis was unremarkable. Bone marrow biopsy, flow cytometry, serum and urine electrophoresis were normal. Autoimmune work-up revealed a positive Anti-Nuclear Antibodies (1:160, Nucleolar staining pattern) with an elevated C4 complement, but was otherwise unremarkable (Table 1). The patient subsequently developed worsening left knee pain and swelling with limited range of motion, prompting arthrocentesis. Synovial fluid analysis demonstrated calcium pyrophosphate deposition (CPPD) and the patient was started on methylprednisolone 40 mg daily with resolution of quotidian fevers as well as improved leukocytosis. She remained afebrile on steroids and was eventually discharged to subacute rehabilitation with intravenous ceftriaxone for a planned 6–8 weeks course for possible spinal discitis/osteomyelitis (despite the noted negative culture and biopsy results) and prednisone taper for CPPD.

Five days after discharge, she developed spiking fevers associated with a diffuse pruritic rash involving the anterior chest and neck and was readmitted to our hospital. No significant changes were noted except for a rapid taper of Prednisone to 10 mg. Physical exam was significant for a fever of 40.3°C and a macular, pink truncal rash. Repeat laboratory findings demonstrated persistent leukocytosis (15.6 k/uL) with neutrophilic predominance (92.4%) and persistently elevated inflammatory markers. Blood cultures were obtained and empiric broad-spectrum antibiotics were initiated. A single dose of methylprednisolone 40 mg IV was administered, leading to fever resolution and improvement of the pruritic rash. Repeat CT scan demonstrated persistent mildly enlarged mediastinal lymph nodes, resolution of the previously observed pleural effusion and ascites, and no

---

**Table 1**

| Test                        | Result                  |
|-----------------------------|-------------------------|
| Ferritin                    | 9617 ng/mL              |
| Leukocytosis                | 20.6 k/uL               |
| Hemoglobin                  | 12.5 g/dL               |
| Red Blood Cell Count        | 4.5 million/µL          |
| Platelets                   | 300 k/µL                |
| Prothrombin Time            | 10 seconds              |
| INR                          | 1.2                     |
| Aspartate Transaminase      | 45 U/L                  |
| Alanine Transaminase        | 30 U/L                  |
| Creatinine                  | 0.9 mg/dL               |
| Sodium                      | 135 mEq/L               |
| Potassium                   | 4.5 mEq/L               |
| Blood Glucose               | 95 mg/dL                |
| Serum Creatinine            | 1.2 mg/dL               |
| Calcium                     | 9.5 mg/dL               |
| Phosphate                   | 4.5 mg/dL               |
| Sodium Chloride             | 135 mEq/L               |
| Hemoglobin A                | 95 g/dL                 |
| Hemoglobin F                | 5 g/dL                  |
| Hemoglobin B                | 95 g/dL                 |
| Hemoglobin C                | 95 g/dL                 |
| White Blood Cell Count      | 4.5 million/µL          |
| Neutrophils                 | 50%                     |
| Lymphocytes                 | 25%                     |
| Monocytes                   | 20%                     |
| Eosinophils                 | 5%                      |
| Basophils                   | 2%                      |
| Histocytes                  | 3%                      |
| Monocytes                   | 20%                     |
| Eosinophils                 | 5%                      |
| Basophils                   | 2%                      |
| Histocytes                  | 3%                      |
| Platelets                   | 300 k/µL                |
| Prothrombin Time            | 10 seconds              |
| INR                          | 1.2                     |
| Aspartate Transaminase      | 45 U/L                  |
| Alanine Transaminase        | 30 U/L                  |
| Creatinine                  | 0.9 mg/dL               |
| Sodium                      | 135 mEq/L               |
| Potassium                   | 4.5 mEq/L               |
| Blood Glucose               | 95 mg/dL                |
| Serum Creatinine            | 1.2 mg/dL               |
| Calcium                     | 9.5 mg/dL               |
| Phosphate                   | 4.5 mg/dL               |
organomegaly. Her antibiotics were switched to meropenem due to concern for osteomyelitis and ultimately discontinued in light of persistently negative blood cultures. Twenty-four hours after discontinuing Meropenem, a time that coincided with tapering of prednisone to 10 mg, she developed fever and a severe, pruritic rash involving the entire trunk (Fig. 5) that disappeared with resolution of fever. Mediastinal lymph node biopsy was deferred due to the high risk of complications. She remained afebrile, and in discussion with Rheumatology, prednisone was tapered to 5 mg, leading to recurrence of fever and the previously noted pruritic rash. Additional diagnostic workup demonstrated negative double stranded DNA antibody, anti-Smith antibody, and normal serum angiotensin converting enzyme. Given the negative workup and fulfillment of Yamaguchi criteria (Table 2), the patient was diagnosed with Adult Onset Still’s Disease. She was started on Ibuprofen 800 mg three times a day and prednisone tapered to 5 mg for 2 days and then discontinued. The patient remained asymptomatic, afebrile and demonstrated improvement in the rash. She was discharged home and instructed to follow-up as outpatient with rheumatology.

Three months later her quotidian fevers and arthralgia recurred and she was admitted to a neighboring medical center. She was evaluated by multiple sub-specialty services, but extensive infectious, autoimmune, and hematological work-up remained negative. She was empirically started on colchicine with some improvement but continued to spike quotidian fevers. Positron Emission Tomography scan showed hilar and supraclavicular lymphadenopathy. An ultrasound-guided biopsy of supraclavicular nodes showed reactive lymphoid tissue without granulomas. She was discharged without a definitive diagnosis and a month later underwent bilateral temporal artery biopsy that was negative for giant cell arteritis. Over the course of the next 2 months she suffered from relapsing symptoms of fever and arthralgia, prompting readmission to the neighboring hospital. Comprehensive evaluation was once again negative except for elevated inflammatory markers (Table 1). Rheumatology re-evaluated the patient and diagnosed her with AOSD. The patient was started on Anakinra 100 mg daily and remained asymptomatic with normal inflammatory markers on outpatient follow-up (Fig. 3).

**Discussion and conclusions**

We performed a web-based search in Medline and Embase databases of English language medical literature using the key terms “Still’s”, “AOSD” and “elderly”, and filtered the search for age 70 years and older. A total of 113 articles were identified. Duplicates and articles other than case reports and series were excluded from the initial pool of articles. Thirty eight case reports and series (e.g. abstracts) [4–41] with a total of 41 individual cases remained and the present case was added to the database, making for a total of 42 individual cases (Fig. 6). We then retrospectively reviewed each case with attention to its demographics (such as gender, age), presenting signs and symptoms, laboratory findings, complications such as macrophage activation syndrome (MAS), time to diagnosis and finally treatment regimens. Collected data were categorized and using SAS University edition, the identified data were analyzed as median ± interquartile range (IQR) or percentage, where appropriate. To compare the patients who developed MAS and
those who did not, we further performed Chi-square/Fisher test and Wilcoxon rank sum test to compare the categorical variables and continuous variables, respectively. Logistic regression analysis was used to analyze factors, including leukocytosis and ferritin level that independently predict MAS. Two-sided hypothesis

| Table 1 Lab values over the course of disease and final diagnosis |
|---------------------------------------------------------------|
| Labs (Range) | Result on Day 0 | Result on Day 28 | Results on Day 120 | Results on Day 180 |
|---------------|-----------------|------------------|--------------------|--------------------|
| WBC (4–10.8 k/uL) | 20.6 | 15.6 | 15 | 14.5 |
| Neutrophil (43–75%) | 91.9 | 92.4 | 86.6 | 94 |
| Lymphocyte (15–45%) | 4 | 4.5 | 8.5 | 2.8 |
| Eosinophil (0–6%) | 0 | 0.3 | 0.1 | 0.1 |
| Hgb (11–14.5 g/dL) | 7 | 7.7 | 8.9 | 7.4 |
| Platelet (145–400 k/uL) | 402 | 243 | 321 | 303 |
| ESR (0–22 mm/hr) | 117 | 60 | 56 | 91 |
| CRP (0–3 mg/L) | > 190 | 88.5 | 15.2 | 18.8 |
| Ferritin (5–148 ng/mL) | 9617 | 4585 | 23,096 | 15,141 |
| AST (3–34 units/L) | 58 | 18 | 41 | 41 |
| ALT (15–41 units/L) | 47 | 14 | 10 | 6 |
| ANA (< 1:40) | 1:160 | Negative | |
| C3 (90–180 mg/dL) | 142 | 110 | 90 | |
| C4 (10–40 mg/dL) | 40.2 | 33 | 24.2 | |
| RF (0–15 IU/mL) | < 10 | 8 | |
| Anti-CCP (0–19 Units) | 11 | Negative | |
| ds-DNA Ab | Negative | |
| Anti-Smith Ab | Negative | |
| ANCA | Negative | Negative | |
| Anti-Ro (SSA) | Negative | Negative | |
| Anti-La (SSB) | Negative | Negative | |
| ACA IgG | Negative | |
| ACA IgM | Negative | |
| IgA (70–400 mg/dL) | 434 | 458 | |
| IgG (700–1600 mg/dL) | 676 | 776 | |
| IgG4 (1–123 mg/dL) | 57 | | |
| IgM | 195 | |
| Free Kappa (3.3–19.4 mg/L) | 85.35 | 36 | |
| Free Lambda (5.71–26.3 mg/L) | 58.33 | 52 | |
| K/L (0.26–1.65) | 1.46 | 0.69 | |
| IL-2 Receptor | 10,000 pg/mL | |
| Haptoglobin (30–200 mg/dL) | 515 | | |
| Absolute Reticulocyte (0.02–0.1 million/μL) | 0.043 | | |
| Vitamin B9 (4.1–55.4 ng/mL) | 15.6 | 12.9 | |
| Vitamin B12 (211–911 pg/mL) | 422 | 807 | |
| Iron (50–170 mcg/dL) | 9 | 17 | |
| TIBC (265–497 mcg/dL) | 115 | 195 | |
| Iron Sat (15–50%) | 8 | 9 | |

WBC White Blood Cell, Hgb Hemoglobin, Ab Antibody, Ig Immunoglobulin, ESR Erythrocyte Sedimentation Rate, CRP C-Reactive Protein, ANA Anti-Neutrophil Antibody, ANCA Anti-Neutrophil Cytoplasmic Antibody, C3 Complement 3, C4 Complement 4, ds-DNA Double-Stranded DNA, RF Rheumatoid Factor, CCP Cyclic Citrulinated Peptide, SS-A Sjögren-Syndrome-related-antigen A, SS-B Sjögren-syndrome-related-antigen B, ACA Anti Cardiolipin Ab, AST Aspartate Aminotransferase, ALT Alanine Aminotransferase, IL Interleukin, TIBC Total Iron Biding Capacity, Sat Saturation
testing was utilized to run statistical analysis and a $p$ value of $<0.05$ was considered statistically significant. All analytic operations were performed using SAS university edition.

The mean age of onset was 76.7 years among all 42 cases. Thirty four cases were reported in women with a female to male ratio of 4 to 1. The most common presenting symptom was fever (100%), with quotidian fever as the predominant pattern. The next most common symptoms on presentation were arthralgia (90.48%) and rash (80.95%) (Table 3). Pruritic rash was reported in 21% of cases with rash. Other less frequently reported features were sore throat (52.38%), hepatosplenomegaly (33.33%), and serositis (16.67%). Macrophage Activation Syndrome (MAS) was reported in nearly 24% of cases without an associated increase in mortality. Leukocytosis was the most prevalent lab finding (78.37%), with a median count of 13,700 (k/uL) and was found to be negatively associated with MAS ($p = 0.04$). Ferritin level greater than 1000 ng/ml was significantly associated with MAS ($p = 0.01$). Elevation of transaminases was present in two thirds of cases but was not associated with MAS. The most common treatment modality was steroids, followed by conventional disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), biologic DMARDs, and miscellaneous therapies, respectively (Table 3). Delayed diagnosis was defined as diagnosis made later than 1 month with a prevalence as high as 90%.

While patients with AOSD typically present with quotidian fever, arthralgia/arthritis, and an evanescent rash [1], a variety of atypical presentations exist. In this case, we describe late onset AOSD in an elderly female who presented outside the classic age distribution with additional atypical features including a pruritic, maculopapular rash. She was noted to have additional findings of cervical and lumbar spinal discitis and CPPD arthropathy, altogether contributing to a diagnostic delay. While CPPD can rarely present with axial skeletal involvement and constitutional symptoms such as fever, the fever
pattern and other accompanying features such as lymphadenopathy and rash makes CPPD unlikely to be the primary underlying pathology. Genetic evaluations was not available in this case however we believe that diseases of genetic mutation like tumor necrosis factor receptor-associated periodic syndrome (TRAPS) and the recently described VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome [42] could be evaluated with genetic testing in appropriate settings. Other autoinflammatory and autoimmune etiologies such as Castleman’s syndrome, necrotizing vasculitis, relapsing polychondritis, Schnitzler’s syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome were excluded based on absence of weight loss, hepatomegaly, splenomegaly, thrombocytopenia, eosinophilia, pancytopenia, unremarkable serum and urine electrophoreses, autoimmune workup, bone marrow, lymph node, and temporal artery biopsies.

Our literature review is limited due to small size and retrospective nature, as well as limitations in regards to patients’ survival and outcome. Nevertheless, it highlights not only AOSD prevalence but characterizes the associated symptoms and laboratory presentations in the elderly. While AOSD in the elderly shares the most common features of AOSD in general population, a variety of key differences exist in the elderly versus classic AOSD populations. We identified a 4 to 1 female to male ratio, which contrasts with the reported distribution of AOSD in general population where males and females are equally affected [1, 2]. Although it may simply be a result of an overall longer life expectancy in women compared to men, it is significant enough to be further investigated in future studies. Another notable finding in our review is the delayed diagnosis, defined as diagnosis made later than 1 month from initial presentation. Whether the delayed diagnosis is limited to elderly population, given their associated multiple comorbidities, is unclear, however it is possible that diagnostic
### Table 2 Yamaguchi’s and Fautrel’s criteria met by patient

| Yamaguchi’s criteria [4]                        | Criteria met by our case | Fautrel’s criteria [5]                        | Criteria met by our case |
|------------------------------------------------|--------------------------|-----------------------------------------------|--------------------------|
| At least 5 criteria including 2 major criteria |                          | 4 major or 3 major and 2 minor criteria       |                          |
| **Major:**                                      |                          |                                               |                          |
| • Fever > 39 °C, lasting 1 week or longer       | +                        | • Spiking fever ≥39 °C                        | +                        |
| • Arthralgia or arthritis, lasting 2 weeks or longer | +                      | • Arthralgia                                | +                        |
| • Typical rash                                  |                           | • Transient erythema                        |                           |
| • Leukocytosis > 10,000/mm³ with > 80%          | +                        | • Pharyngitis                               | -                        |
| polymeronuclear cells                           |                           | • Polymorphonuclear cells ≥80%              | +                        |
|                                                 |                          | • Glycosylated ferritin ≤20%                 |                          |
| **Minor:**                                      |                          |                                               |                          |
| • Sore throat                                   | -                        | • Maculopapular rash                        | +                        |
| • Lymphadenopathy                               | +                        | • Leukocytosis ≥10,000/mm³                  | +                        |
| • Hepatomegaly or splenomegaly                  | -                        |                                               |                          |
| • Abnormal liver function tests                 | +                        |                                               |                          |
| • Negative tests for antinuclear antibody and rheumatoid factor | −/+                     |                                               |                          |
| **Exclusion:**                                  |                          |                                               |                          |
| • Infections                                    | +                        |                                               |                          |
| • Malignancies (mainly malignant lymphoma)      | +                        |                                               |                          |
| • Other rheumatic disease (mainly systemic vasculitides) | +                     |                                               |                          |

*aThe evanescent rash in our case presented on 2nd admission and was pruritic, therefore not meeting the Yamaguchi’s criteria*

---

**Inclusion criteria**

Search terms: Still’s and/or AOSD and Elderly

Search limits:
- Items with abstracts
- Items with search terms in title
- Items published in English

English literature (since 1991):
- Medline
- EMBASE

**Exclusion criteria:**
- Items other than case reports or case series
- Age < 70 years old
- Duplicates

**Abstracts screened**

(n=113)

**Screening**

- All retrieved citations entered into EndNote library where duplicates were identified and deleted
- Titles and abstracts are screened for relevance based on predefined eligibility criteria
- Full-text articles for eligible abstracts were reviewed for inclusion

**Final articles reviewed:**

38 (41 individual cases)

Current case was added to the data base

**Final cases included in analysis:**

42

---

**Fig. 6 Literature review flow chart**
delay may also exist in the younger population. We propose that the delayed diagnosis is likely related to the complicated nature and presentation of AOSD as well as divergence from classic diagnostic criteria in the elderly population.

The characteristic rash of AOSD is an evanescent, maculopapular pink rash that appears during febrile episodes on the extremities, trunk, and neck. Although Yamaguchi’s criteria characterize the rash as nonpruritic [43], pruritic rash and atypical skin manifestations have been reported [44] and were also present in 21% of elderly AOSD cases in our review. This finding calls for attention as it diverges from the classic non-pruritic rash of Yamaguchi criteria, which is the most widely universally used diagnostic criteria by clinicians. This can potentially lead to missed cases of AOSD whom present with atypical symptoms such as pruritic rash, delaying diagnosis and treatment.

While MAS was noted in 24% of elderly AOSD cases in our review, there was minimal mortality, in contrast to the noted mortality associated in younger populations [45, 46]. Although this discrepancy can be a result of limitation of our review in assessing the survival of each case, hypothetically it could be attributed to immune system senescence in elderly population [47] and mandates further investigations. In a recent epidemiologic study of AOSD patients from a nationwide inpatient sample database, the prevalence of MAS, disseminated intravascular coagulopathy (DIC), and thrombotic thrombocytopenic purpura (TTP) was reported to be 1.7, 1.1, and 0.4% respectively with overall inpatient mortality of 2.6%, with the highest mortality in cases of DIC [45]. The negative association of leukocytosis with MAS in our analysis, is well established in MAS cases, however this is limited in our analysis as timing of leukocyte count in regard to MAS could not be evaluated due to limitations of the case reports.

Table 3

| Clinical Characteristics | Total (N, %) | Patients with MASb (N, row %) | Patients without MAS (N, row %) | p-value* |
|--------------------------|-------------|-------------------------------|-------------------------------|----------|
| Patient count            | 42 (100%)   | 10 (23.81%)                   | 32 (76.19%)                   | 0.49     |
| AGE (YEAR), (MEDIAN, IQR)| 75, 7       | 74.5, 8                       | 75, 6                         |          |
| Female                   | 34 (80.95%) | 10 (23.81%)                   | 24 (57.14%)                   | 0.16     |
| Fever                    | 42 (100%)   | 10 (23.81%)                   | 32 (76.19%)                   | 1.00     |
| Rash                     | 34 (80.95%) | 10 (23.81%)                   | 24 (57.14%)                   | 0.16     |
| Pruritic rash            | 9 (21.43%)  | 4 (9.52%)                     | 5 (11.90%)                    | 0.23     |
| Arthralgia/Myalgia       | 38 (90.48%) | 7 (16.67%)                    | 31 (73.81%)                   | 0.04     |
| Serositis                | 7 (16.67%)  | 1 (2.38%)                     | 6 (14.29%)                    | 0.49     |
| Hepatosplenomegaly       | 14 (33.33%) | 3 (7.14%)                     | 11 (26.19%)                   | 0.06     |
| Sore throat              | 22 (52.38%) | 5 (11.90%)                    | 16 (38.10%)                   | 0.31     |
| Leukocytosis, (Median, IQR)| 13,700, 8800| 9000, 5895                  | 16,000, 9470                  | < 0.01   |
| Hyperferritinemia, (Median ± IQR)| 5336, 15,447| 41,932, 70,250            | 2684, 7821                    | < 0.01   |
| Transaminitis            | 28 (66.67%) | 7 (16.67%)                    | 21 (50.0%)                    | 1.00     |
| Delayed Diagnosis (> 1 month) | 38 (90.48%) | 9 (21.43%)             | 29 (69.05%)                   | < 0.01   |
| Corticosteroids          | 39 (92.36%) | 9 (21.43%)                    | 30 (71.43%)                   | 0.28     |
| NSAIDsc                  | 14 (33.33%) | 1 (2.38%)                     | 13 (30.95%)                   | 0.04     |
| Conventional DMARDs d    | 17 (40.48%) | 5 (11.90%)                    | 12 (28.57%)                   | 0.15     |
| Biologic DMARDs          | 8 (19.05%)  | 3 (7.14%)                     | 5 (11.90%)                    | 0.09     |
| Miscellaneous Treatment  | 8 (19.05%)  | 3 (7.14%)                     | 5 (11.90%)                    | 0.09     |

* All percentages are based on the overall patients in total (42 patients)
*b MAS Macrophage activation syndrome
*c NSAIDs Nonsteroidal anti-inflammatory drugs
*d DMARDs Disease-modifying anti-rheumatic drugs
*p Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test was applied where it is appropriate. Statistical tests used two-sided hypothesis testing
ferritin greater than 1000 ng/ml was statistically associated with MAS with a p-value less than 0.01.

Of note in a very recent assessment of Japanese elderly AOSD patient population [50], authors reported similar findings to our review with female predominance, atypical skin lesions, and higher prevalence of complications such as DIC and MAS, however, these findings along with findings of our literature review underscore the need for better characterization of AOSD in the elderly.

The complicated course of the present case and results of our literature review highlight the prevalence of atypical presentations of AOSD in the elderly. Notable distinguishing features include a female predominance, a pruritic rash, a mildly increased evidence of MAS, and a lower MAS-associated mortality rate in this age group. Thus, we conclude that old age and pruritic rash should not be considered exclusionary for AOSD and that current available criteria, although helpful, are not absolute, especially in cases with atypical features. This review, although limited due to small sample size, retrospective nature and lack of a comparison group, emphasizes the need for further investigations to identify potential disease markers and development of alternative diagnostic criteria for those at extremes of age and potentially a unifying and globally accepted diagnostic criteria for AOSD.

Abbreviations
AOSD: Adult onset Still's disease; CT: Computed tomography; MRI: Magnetic resonance imaging; HIV: Human immunodeficiency virus; CPPD: Calcium pyrophosphate deposition; MAS: Macrophage activation syndrome; IQR: Interquartile range; DMARDs: Disease modifying anti-rheumatic drugs; NSAIDs: Non-steroidal anti-inflammatory drugs; TRAPS: Tumor necrosis factor receptor-associated periodic syndrome; DRESS: Drug reaction with eosinophilia and systemic symptoms; DIC: Disseminated intravascular coagulopathy; TTP: Thrombotic thrombocytopenic purpura; VEXAS: Vacuoles, eosinophilia and systemic symptoms; DIC: Disseminated intravascular coagulopathy; E1 enzyme, X-linked, autoinflammatory, somatic

Acknowledgements
Authors would like to thank Sameer Desale and Stephen J Fernandez form MedStar Health research institute for their guidance and contributions to this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

References
1. Riera Alonso E, O. MA. Adult-onset still disease. In: Hochberg MC, editor. Rheumatology. Philadelphia: Elsevier; 2019. p. 1457–44.
2. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
3. Gerfault-Valentin M, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–22.
4. Koga T, et al. A 72-year-old female with adult Still’s disease. Intern Med. 1992;31(12):1356–8.
5. Steffe LA, Cooke CL. Still’s disease in a 70-year-old woman. JAMA. 1983;249(15):2062–3.
6. Uson J, et al. Still’s disease in a 72-year-old man. J Rheumatol. 1993;20(9):1608–9.
7. Sato M, et al. Adult Still’s disease with Sjögren’s syndrome successfully treated with intravenous pulse methylprednisolone and oral cyclophosphamide. Intern Med. 1993;32(9):730–2.
8. Tamura K, et al. Elderly onset of adult Still’s disease: report of a case. Clin Rheumatol. 1994;13(1):117–8.
9. Take H, et al. Successful treatment with auranofin in a patient with elderly-onset Still’s disease. J Med. 1994;25(6):393–7.
10. Takami A, et al. Adult-onset Still’s disease with substantive massive necrosis. Intern Med. 1995;34(2):89–91.
11. Kurabayashi H, et al. Cerebral haemorrhage complicating adult-onset Still’s disease: a case report. J Int Med Res. 1996;24(6):492–4.
12. Mok CC, Lau CS, Wong RWS. Still’s disease in an 80-year-old woman. Age and Aging. 1998;27(3):407–9.
13. Koizumi R, et al. Treatment of adult Still’s disease with dexamethasone, an alternative to prednisolone. Scand J Rheumatol. 2000;29(6):396–8.
14. Stoica GS, Cohen RI, Rossoff LJ. Adult Still’s disease and respiratory failure in a 74 year old woman. Postgrad Med J. 2002;78(916):97–8.
15. Rubenstein EJ, Arkfeld DG. Adult Still’s disease in a 75-year-old patient. J Am Geriatr Soc. 2004;52(12):2144–5.
16. Hamidou MA, et al. Usefulness of glycosylated ferritin in atypical presentations of adult onset Still’s disease. Ann Rheum Dis. 2004;63(S):605.
17. Amenomori M, et al. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still’s disease. Clin Exp Rheumatol. 2005;23(1):100–2.
18. Kurasawa M, et al. Adult-onset Still’s disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy. Age Ageing. 2007;36(1):104–6.
19. Vilà LM, Molina MJ. Chronic anemia and thrombocytosis as the initial presentation of Still’s disease in an elderly patient. Gerontology. 2007;53(5):289–92.
20. Izumikawa K, et al. Adult Still’s disease associated with cytomegalovirus infection. J Infect Chemother. 2007;13(2):114–7.
21. Choe JY, et al. Clinical significance of 18F-fluoro-deoxyglucose positron emission tomography in patients with adult-onset Still’s disease: report of two cases and review of literatures. Rheumatol Int. 2010;30(12):1673–6.
22. Yoo WH. Adult onset Still’s disease following influenza vaccination. Joint Bone Spine. 2010;77(4):373–4.
23. Apostolova M, Shoib M, Glynn M. A rare presentation of adult onset Still’s disease in an elderly patient. Rheumatol Rep. 2011;3(1):10.
24. Ertugrul BM, et al. Adult-onset Still’s disease in an 83-year-old. J Am Geriatr Soc. 2012;60(1):162–4.
25. Kumaki D, et al. Efficacy of denosumab for osteoporosis in two patients with adult-onset Still’s disease—denosumab efficacy in osteoporotic Still’s disease patients. J Clin Med. 2018;7(4):63.
26. Kumano T, et al. Adult-onset Still’s disease in an elderly woman with atypical presentation. Case Rep Internal Med. 2014;1(2).
27. Kiyonaga Y, et al. Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still’s disease. Intern Med. 2014;53(11):1209–13.
28. Umeda M, et al. Hemophagocytic syndrome and inflammatory myopathy with abundant macrophages in a patient with adult-onset Still’s disease. Intern Med. 2014;53(20):2385–9.
29. Kikuchi N, et al. Persistent pruritic papules and plaques associated with adult-onset Still’s disease: report of six cases. J Dermatol. 2014;61(3):561–2.
30. Watanabe E, et al. Successful Tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med. 2016;2016:5565320.
31. Yamada S, et al. Extremely high serum ferritin: an instrumental marker of macroagranular adult-onset Still’s disease with Hemophagocytic syndrome. Am J Case Rep. 2017;18:296–301.
32. Liu Y, et al. Two severe cases of adult-onset Still’s disease with persistent pruritic eruptions. Acta Derm Venereol. 2018;98(5):524–5.
33. Uchida T, et al. Gastric mucormycosis complicated by a gastropleural fistula: a case report and review of the literature. Medicine (Baltimore). 2019;98(48):e18142.
34. Rossio R, et al. Adult-onset still disease after human herpesvirus 6 infection in an elderly patient: a case report. JCR. 2019. Publish Ahead of Print.
35. Goh Y, et al. An unusual cause of acute ischemic stroke: adult onset Still’s disease. J Thromb Thrombolysis. 2020;49(1):141–4.
36. Suda T, et al. Elderly-onset Still’s disease complicated by macrophage activation syndrome: a case report and review of the literature. Intern Med. 2020;59(5):721–8.
37. Kamada M, Kozakata T. Effectiveness of profiling serum IL-18 and Neopterin in diagnosis of adult-onset Still’s disease complicated by pulmonary tuberculosis: a case report. Tohoku J Exp Med. 2020;250(4):201–6.
38. Ohtani S, et al. Successful use of short-term add-on tocilizumab for refractory adult-onset Still’s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide. Modern Rheumatol Case Rep. 2020;4(2):1–6.
39. Kato T, et al. Angioedema of the periorbital region that developed during treatment with etanercept in a case of refractory adult-onset Still’s disease. Intern Med. 2012;51(19):2801–4.
40. Beck DB, et al. Somatic mutations in. N Engl J Med. 2020;383(27):2628–38.
41. Yamamoto T, et al. Cutaneous manifestations associated with adult-onset Still’s disease: important diagnostic values. Rheumatol Int. 2012;32(5):2233–7.
42. Mehta BY, et al. Racial/ethnic variations in morbidity and mortality in adult onset Still’s disease: an analysis of national dataset. Semin Arthritis Rheum. 2019;49(3):469–73.
43. Giunco S, et al. Immune senescence and immune activation in elderly colorectal cancer patients. Aging (Albany NY). 2019;11(11):3864–75.
44. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401–9.
45. Faustoi B. Adult-onset still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773–92.
46. Salaffi F, et al. Urticaria as a presenting manifestation of adult-onset Still’s disease. Clin Rheumatol. 2000;19(5):389–91.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.